The estimated Net Worth of Brendan P. Eckelman is at least $36.9 Million dollars as of 28 May 2024. Dr Eckelman owns over 300,000 units of Inhibrx stock worth over $26,033,295 and over the last few years he sold INBX stock worth over $10,290,000. In addition, he makes $589,749 as Founder and Chief Scientific Officer & Exec. VP of Corp. Strategy at Inhibrx.
Dr has made over 1 trades of the Inhibrx stock since 2024, according to the Form 4 filled with the SEC. Most recently he sold 300,000 units of INBX stock worth $10,290,000 on 28 May 2024.
The largest trade he's ever made was selling 300,000 units of Inhibrx stock on 28 May 2024 worth over $10,290,000. On average, Dr trades about 75,000 units every 0 days since 2024. As of 28 May 2024 he still owns at least 1,735,553 units of Inhibrx stock.
You can see the complete history of Dr Eckelman stock trades at the bottom of the page.
Dr. Brendan P. Eckelman Ph.D. is the Founder, Chief Scientific Officer & Exec. VP of Corp. Strategy at Inhibrx.
As the Founder and Chief Scientific Officer & Exec. VP of Corp. Strategy of Inhibrx, the total compensation of Dr D at Inhibrx is $589,749. There are 2 executives at Inhibrx getting paid more, with Mark Paul Lappe having the highest compensation of $994,281.
Dr D is 42, he's been the Founder and Chief Scientific Officer & Exec. VP of Corp. Strategy of Inhibrx since . There are 3 older and 1 younger executives at Inhibrx. The oldest executive at Inhibrx, Inc. is Mark Paul Lappe, 54, who is the Founder, Chairman, Pres & CEO.
Brendan's mailing address filed with the SEC is C/O INHIBRX, INC., 11025 NORTH TORREY PINES ROAD, SUITE 140, LA JOLLA, CA, 92037.
Over the last 4 years, insiders at Inhibrx have traded over $27,711,393 worth of Inhibrx stock and bought 2,717,119 units worth $64,845,764 . The most active insiders traders include Global Investors Lp Viking ..., Capital Management, L.P.Kol..., and Global Investors Lp Viking .... On average, Inhibrx executives and independent directors trade stock every 42 days with the average trade being worth of $1,598,400. The most recent stock trade was executed by Mark Lappe on 6 September 2024, trading 44,000 units of INBX stock currently worth $671,000.
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
Inhibrx executives and other stock owners filed with the SEC include: